Drug Trial Radar · NCT07177716
Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Oct 2025
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- L & L Bio Co., Ltd., Ningbo, ChinaIndustry
- Sponsor type
- Industry
- First posted
- Sep 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label Phase II/III clinical study, aiming to evaluate the efficacy and safety of LB1410 in combination with lenvatinib (whether in combination with LB4330)versus the chemotherapy regimen selected by the investigators for patients with advanced recurrent/metastatic cervical cancer.
Conditions
- Cervical Cancer
Interventions
LB1410Biological
LB1410 (IV, Q2W for up to 2 years)
LB4330Biological
LB4330 (IV, Q2W for 4 cycles)
LenvatinibDrug
lenvatinib (oral, once daily for up to 2 years)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) assessed by an Independent Radiology Review Committee (IRRC)Time frame: Approximately 24 months
- Duration of Response (DOR) assessed by an Independent Radiology Review Committee (IRRC)Time frame: Approximately 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.